ProfileGDS5678 / 1434130_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 78% 79% 79% 80% 82% 81% 79% 81% 73% 73% 77% 77% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9914883
GSM967853U87-EV human glioblastoma xenograft - Control 25.3771978
GSM967854U87-EV human glioblastoma xenograft - Control 35.5527179
GSM967855U87-EV human glioblastoma xenograft - Control 45.6379
GSM967856U87-EV human glioblastoma xenograft - Control 55.6954880
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.795282
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6332681
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4893479
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7341181
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7854473
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6837773
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2531977
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.2483977
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3012178